Method for treating neurodegenerative diseases
View Patent ↗The present invention is directed to a method for treating a neurodegenerative disease such as amyotrophic lateral sclerosis (ALS), Alzheimer disease, Parkinson's disease, Huntington's disease, frontotemporal degeneration, dementia with Lewy bodies, a motor neuron disease, or a demyelinating disease. The method comprises administering to a subject in need thereof a Ppargc1a activator 2-(4-tert-butylphenyl)-1H-benzimidazole, 2-[4-(1,1-dimethylethyl)phenyl]-1H-benzimidazole, in an effective amount. A preferred route of administration is oral administration.
1. A method of suppressing microglia-mediated inflammation in a subject diagnosed with a neurodegenerative disease, comprising the step of administering to a subject suffering from a neurodegenerative disease an effective amount of 2-(4-tert-butylphenyl)-1H-benzimidazole.
2. The method of claim 1 , wherein the neurodegenerative disease is selected from the group consisting of: amyotrophic lateral sclerosis (ALS), Alzheimer disease, Parkinson's disease, Huntington's disease, frontotemporal degeneration, dementia with Lewy bodies, a motor neuron disease, and a demyelinating disease.
3. The method according to claim 1 , wherein said compound is administered by systemic administration.
4. The method according to claim 1 , wherein said compound is administered by oral administration.
5. The method of claim 2 , wherein the neurodegenerative disease is ALS.
6. The method of claim 2 , wherein the neurodegenerative disease is Alzheimer's disease.
7. The method of claim 2 , wherein the neurodegenerative disease is Parkinson's disease.
8. The method of claim 2 , wherein the neurodegenerative disease is Huntington's disease.
9. The method of claim 2 , wherein the neurodegenerative disease is frontotemporal degeneration.
10. The method of claim 2 , wherein the neurodegenerative disease is dementia with Lewy bodies.
11. The method of claim 2 , wherein the neurodegenerative disease is a motor neuron disease.
12. The method of claim 2 , wherein the neurodegenerative disease is a demyelinating disease.
13. The method of any one of claims 5 - 12 , wherein said compound is administered by systemic administration.
14. The method of any one of claims 5 - 12 , wherein said compound is administered by oral administration.